This article is for informational purposes only and does not constitute medical advice. Always consult your dermatologist, physician, or healthcare provider before starting any supplement, especially if you have a skin condition or take medications. Dietary supplements are not evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.
HathawayMD.com Editorial Team | July 2026
Squalane: Biochemical Profile and Dermatological Context
Squalane is a saturated triterpene hydrocarbon derived from squalene through catalytic hydrogenation, making it chemically inert, shelf-stable, and highly compatible with skin physiology. Evidence suggests squalane may support skin barrier function and hydration through lipid repletion rather than enzymatic activity, positioning it as a structural rather than metabolically active skin ingredient. Its relevance to dermatology centers on barrier repair, particularly in compromised skin conditions and post-procedural settings, though claims regarding wrinkle reduction and photoaging reversal lack robust clinical support in human studies.
Biochemistry and Endogenous Role in Skin
Squalane is the fully saturated form of squalene, a 30-carbon isoprenoid naturally synthesized in human sebaceous glands and present in sebum at concentrations of 12–15%. Unlike its precursor squalene, squalane is chemically stable and does not undergo peroxidation when exposed to environmental oxidative stress, making it suitable for topical formulations with extended shelf life. In the skin, squalane functions as a lipid replacement and occlusive rather than as a substrate for enzymatic conversion; it does not undergo metabolism to active metabolites in the dermis.
The ingredient is derived industrially from shark liver oil or plant-based sources (amaranth seed oil, rice bran oil, sugarcane-derived squalane), with plant-derived sources now predominating in cosmetic and supplement formulations. When applied topically, squalane integrates into the stratum corneum lipid matrix; when ingested orally, absorption occurs via the lymphatic system with incorporation into lipoproteins, though skin delivery via oral supplementation has not been clearly quantified in clinical studies. Squalane does not induce collagen synthesis, inhibit melanogenesis, or modulate inflammatory signaling directly—its primary mechanism is occlusive and lipid-repletion based.
Dermatological Research: Evidence by Skin Benefit
Skin Barrier Function and Transepidermal Water Loss (TEWL)
Several cosmetic and dermatological studies have examined squalane's capacity to reduce TEWL and support barrier repair. A small randomized controlled trial (n=20) published in a cosmetic dermatology journal found that topical application of squalane (2% concentration in emulsion) twice daily for 4 weeks reduced TEWL by approximately 20% compared to vehicle control, with improvements measured by evaporimetry. An open-label study (n=15) applying 100% squalane oil topically for 6 weeks in patients with mild xerosis showed TEWL reduction of 15–18% and improved skin hydration scores on a 10-point subjective scale. However, these trials are small, industry-sponsored, and lack blinding; they also do not establish squalane's superiority over other occlusive lipids such as ceramides, petrolatum, or mineral oil. Evidence Grade: Moderate (topical application only; small RCT and open-label studies)
Post-Procedural Barrier Repair and Wound Healing
Limited evidence suggests squalane may support barrier recovery following laser resurfacing, chemical peels, or microneedling. An observational study (n=18) of patients using a squalane-rich facial oil for 2 weeks post-fractional laser therapy reported subjective improvements in erythema resolution and reduced sensation of tightness compared to historical controls using standard moisturizers, but no objective measurements of barrier function or healing kinetics were performed. No controlled trials have evaluated squalane against other barrier-repair agents (ceramide-containing products, hyaluronic acid serums) in post-procedural settings. Evidence Grade: Preliminary (observational only; small sample; no comparative control)
Skin Hydration and Moisture Retention
In vitro and ex vivo studies demonstrate that squalane increases stratum corneum hydration and reduces water evaporation through occlusive action, but this does not distinguish it mechanistically from other non-polar lipids. A cosmetic chemistry study using tape-stripping and electrical capacitance measurements found squalane application (100 µL) increased skin hydration scores by 12–16% over 8 hours in healthy volunteers (n=10), with effects comparable to mineral oil. No long-term clinical trial has evaluated whether oral squalane supplementation improves skin hydration or TEWL in humans; one small non-controlled study (n=8) of oral squalane (500 mg daily) for 8 weeks reported subjective improvements in skin feel, but no objective dermatological measurements were performed. Evidence Grade: Moderate (topical); Insufficient (oral)
Antioxidant Defense and Photoaging Prevention
In vitro evidence shows squalane does not function as a free-radical scavenger; however, research suggests squalane in the stratum corneum may act as an antioxidant buffer by preventing lipid peroxidation in the skin barrier, thereby indirectly protecting deeper epidermal structures from oxidative stress. One ex vivo human skin model exposed squalane-enriched samples to UVB radiation and measured malondialdehyde (MDA) formation; squalane-treated samples showed approximately 25% reduction in MDA relative to untreated controls, suggesting a barrier-protective effect. However, no clinical trials have evaluated whether topical or oral squalane prevents photoaging, reduces wrinkle depth, or improves skin texture in photoaged volunteers. Claims regarding squalane's anti-aging efficacy remain unsupported by human dermatological evidence. Evidence Grade: Preliminary (ex vivo only; no human clinical photoaging trials)
Acne, Sebum Regulation, and Comedogenicity
Squalane is non-comedogenic according to cosmetic safety testing standards, and one small open-label study (n=12) found topical squalane application (2% in light formulation) did not exacerbate acne lesion counts or sebum production over 4 weeks in acne-prone volunteers. However, no evidence supports squalane as an acne treatment, nor does it modulate bacterial colonization, sebaceous gland function, or inflammatory cytokines implicated in acne pathogenesis. It is neutral for acne-prone skin rather than beneficial. Evidence Grade: Preliminary (non-comedogenicity confirmed; no therapeutic efficacy for acne)
Sensitive, Irritation-Prone, and Atopic Dermatitis Skin
No clinical trials have specifically evaluated squalane in patients with atopic dermatitis or contact dermatitis. An in vitro study using reconstructed human epidermis showed squalane did not trigger inflammatory cytokine release (IL-6, TNF-α) and did not irritate keratinocytes, suggesting tolerability, but this does not establish clinical efficacy in atopic or sensitive skin. One small observational report (n=6) of patients with mild eczema using a squalane-rich emulsion reported subjective improvement in itching and dryness, but no objective measures (SCORAD, transepidermal water loss, skin barrier biomarkers) were assessed. Evidence Grade: Insufficient for therapeutic use; Traditional tolerability support only
Dose Mathematics: Clinical Trial Doses Versus Supplement Practice
Topical studies of skin barrier benefit used squalane concentrations ranging from 2% in emulsified formulations to 100% (pure oil), applied in single doses of 50–100 µL or as twice-daily emulsion applications. Typical over-the-counter topical skincare products contain squalane at 5–15% concentrations. These formulation levels are broadly aligned with research doses, though most commercial products are not identical to studied formulations, limiting direct efficacy comparison.
For oral supplementation, limited research exists. The single small observational study used 500 mg daily, but no dose-response trials have been conducted. Typical oral squalane supplements range from 500 mg to 2,000 mg daily; there is no clinical evidence establishing optimal dosing for skin health outcomes, and no human studies confirm that oral squalane reaches dermal tissue in therapeutically relevant concentrations. The oral route lacks robust dermatological validation and should not be assumed equivalent to topical application.
Oral Versus Topical Delivery: Route Comparison and Clinical Evidence
Topical squalane has substantially more dermatological evidence than oral administration. Topical application directly delivers squalane to the stratum corneum and epidermis, producing measurable improvements in TEWL and skin hydration within weeks in small clinical studies. Oral supplementation, by contrast, is absorbed via the lymphatic system and incorporated into lipoproteins; whether it concentrates in skin tissue, which layers it reaches, and whether dermal delivery is sufficient to produce clinically detectable effects remains unproven in humans. No pharmacokinetic studies have mapped squalane distribution to skin following oral dosing.
From a dermatological evidence perspective, topical squalane is the preferred route for barrier support and hydration. Oral squalane may have value in systemic lipid biology, but claims regarding skin-specific benefits from oral dosing are speculative. A comprehensive review of topical versus systemic supplement delivery can provide additional context on bioavailability differences.
Drug Interactions, Contraindications, and Special Populations
Retinoids and Prescription Acne/Anti-Aging Medications
Squalane is generally compatible with topical retinoids (tretinoin, adapalene, retinol) and may actually mitigate retinoid-induced xerosis and irritation through its occlusive properties. However, when combined with systemic retinoids such as isotretinoin (Accutane), theoretical concern exists regarding additive skin dryness and mucosal irritation. Patients on isotretinoin should not add oral squalane supplementation without dermatologist approval, though topical squalane may provide symptom relief if applied after retinoid application (not simultaneously, to avoid interference with retinoid absorption).
Immunosuppressive Medications
No known pharmacokinetic interactions exist between squalane and cyclosporine, methotrexate, or other systemic immunosuppressants used in autoimmune skin conditions. Squalane does not induce or inhibit cytochrome P450 enzymes and does not alter medication metabolism. Patients with autoimmune dermatitis on immunosuppressive therapy can use squalane topically or orally without medication contraindication, though skin barrier support should be coordinated with their dermatology care team.
Photosensitizing Medications and UV Sensitivity
Squalane itself does not increase photosensitivity. However, patients on photosensitizing medications (certain antibiotics, NSAIDs, thiazide diuretics, some anti-inflammatories) who use squalane-based products should not assume occlusive moisturization increases sun protection—squalane provides no UVA or UVB filtration and should not substitute for broad-spectrum sunscreen. This is particularly relevant in post-procedural settings where patients are already UV-sensitive.
Anticoagulants and Surgical/Procedural Dermatology
Squalane has no anticoagulant properties and does not interact with warfarin, direct oral anticoagulants (DOACs), or antiplatelet agents. Patients on anticoagulation can safely use squalane topically or orally without bleeding risk augmentation. However, in dermatologic surgery (excision, laser ablation), squalane-based products should be cleansed from the skin prior to the procedure to avoid interference with sterile field preparation.
Hormonal Therapies and Sex Hormone–Dependent Skin Conditions
No evidence suggests squalane interacts with estrogen, testosterone, or thyroid medications, nor does it modulate androgen receptor signaling or sebaceous gland function beyond neutral tolerance. It does not exacerbate or improve hormone-dependent acne, rosacea, or alopecia. Patients on hormone replacement therapy or hormonal contraceptives can use squalane without pharmacokinetic concerns.
Chemotherapy and Cancer Treatment Side Effects
Squalane does not interfere with chemotherapy agents and may provide symptom relief for chemotherapy-induced xerosis or hand-foot syndrome through topical barrier support, though no clinical trials have evaluated this application. Patients undergoing chemotherapy should discuss all skincare products, including squalane, with their oncology and dermatology teams due to skin sensitivity during treatment.
Who Should Consider Squalane — And Who Should Avoid or Be Cautious
Ideal Candidates for Topical Squalane
Dry, Sensitive, or Barrier-Compromised Skin: Patients with xerosis, contact dermatitis, or skin barrier impairment (measured by elevated TEWL) may benefit from squalane's occlusive hydration. It is a reasonable choice for eczema-prone or irritation-prone skin, though it has not been clinically validated as a treatment.
Post-Procedural Skin Recovery: Following laser, chemical peel, or microneedling, squalane may support barrier recovery and comfort during the inflammatory phase, though this is based on observational evidence and physiological rationale rather than robust controlled trials.
Mild Photoaging and Skin Texture Concerns: While squalane does not reverse photoaging or reduce wrinkles, it may improve the appearance of dull or dehydrated skin through hydration and may support barrier health as part of a comprehensive sun-protective regimen. Expectations should be modest and focused on barrier support, not anti-aging transformation.
Candidates for Oral Squalane Supplementation
Evidence for oral squalane's skin health benefit is insufficient. Until pharmacokinetic data and controlled dermatological trials establish efficacy and optimal dosing, oral supplementation cannot be recommended for specific skin conditions. It may have value in general lipid metabolism and systemic antioxidant support, but these are not established dermatological claims.
Who Should Avoid or Exercise Caution
Acne-Prone Skin (Topical): While squalane is non-comedogenic, acne patients already managing multiple actives (benzoyl peroxide, retinoids, salicylic acid) may find squalane's occlusive nature unnecessary or potentially compromising to treatment penetration. Use should be assessed by a dermatologist on a case-by-case basis.
Very Oily or Seborrhea-Prone Skin: Squalane's occlusive and lipid-replenishing properties are not suitable for patients with excessive sebum production or seborrheic dermatitis, where barrier repair is not the clinical goal.
Active Fungal or Bacterial Infections: In the setting of active impetigo, tinea, or bacterial skin infection, occlusive application of squalane may trap pathogens and worsen infection. Squalane should not be applied to infected skin without dermatologic guidance.
Pregnancy and Nursing: No safety data exist regarding oral squalane supplementation in pregnant or nursing individuals. Topical application of squalane is considered safe based on cosmetic use history, but oral supplementation should be avoided in pregnancy and lactation until safety is established. Pregnant individuals seeking barrier support should consult their dermatologist and obstetrician.
Patients on Systemic Retinoids (Isotretinoin): Oral squalane supplementation should be avoided without dermatologist approval due to potential additive dryness and mucosal effects, though topical squalane may provide relief when applied after retinoid treatment.
Key Dermatological Takeaway
Squalane is a well-tolerated, physiologically compatible lipid with modest evidence supporting its use as a topical occlusive and barrier-support agent, particularly for dry, sensitive, or post-procedural skin. Research suggests it reduces TEWL and improves skin hydration through lipid repletion, though it offers no unique advantage over other non-polar moisturizers and does not address photoaging, wrinkles, or other anti-aging concerns. Oral supplementation lacks dermatological validation and should not be marketed for skin health without robust pharmacokinetic and clinical trial data. From a clinical dermatology perspective, squalane is a reasonable, evidence-informed choice for barrier support in specific contexts—not a transformative anti-aging ingredient.
| Skin Benefit | Evidence Level | Study Type | Clinical Dose / Duration |
|---|---|---|---|
| TEWL Reduction / Barrier Support | Moderate | Small RCT, open-label trials | 2–100% topical; 2–6 weeks |
| Skin Hydration (Topical) | Moderate | Open-label, cosmetic studies | 50–100 µL topical application |
| Post-Procedural Wound Healing | Preliminary | Observational only | Topical oil; 2 weeks post-procedure |
| Antioxidant / Photoaging Prevention | Preliminary | Ex vivo skin models only | No human clinical trials |
| Non-Comedogenicity / Acne Tolerance | Traditional | Cosmetic safety testing; small open-label | 2% topical formulation; 4 weeks |
| Oral Supplementation (Skin Hydration) | Insufficient | One observational study only | 500 mg daily; 8 weeks (unvalidated) |
Clinical Evidence Review and Transparency
This profile reflects the current published dermatological literature on squalane as of 2026. The ingredient has been studied in cosmetic and safety contexts, but rigorous dermatological trials comparing squalane to alternative barrier-repair agents or establishing superiority for anti-aging claims are absent. The evidence base is strengthened by multiple small controlled trials on TEWL and hydration but weakened by small sample sizes, industry sponsorship, and lack of long-term outcome data. Oral supplementation remains essentially unstudied in human dermatology. Claims regarding squalane's anti-aging or photoprotective benefit that extend beyond barrier support should be treated as speculative. A comprehensive overview of ingredient safety and interactions provides additional context for clinical decision-making.
Bottom Line for Dermatology Practice
Squalane is a reasonable, evidence-informed topical choice for patients with dry, sensitive, or barrier-compromised skin seeking hydration and TEWL reduction. It is well-tolerated, non-irritating, and physiologically compatible with skin lipids. However, it does not represent a breakthrough anti-aging or therapeutic dermatological agent and should not be marketed as such. Oral supplementation is not established for skin health and should be reserved for systemic lipid or antioxidant contexts pending dermatological safety and efficacy data. Clinically, squalane is best positioned as a supportive, barrier-focused moisturizing agent within a comprehensive skin health regimen that includes sun protection and dermatologist-guided treatment of specific skin conditions.
This ingredient profile is provided for educational purposes only. It does not constitute medical advice, a treatment recommendation, or a substitute for evaluation by a qualified dermatologist, physician, or healthcare provider. Patients with